Cannabinoids As Drugs – Latest Updates

• OVERVIEW

This webinar will discuss the current status of cannabinoids as medical products in the United States.  The focus will be on what we can learn from the FDA approval of Epidolex (Cannabidiol) oral solution 100 mg/mL.  How to obtain research information will be presented.  The current market for Cannabidiol (CBD) in the United States will also be discussed.  This information may be useful in predicting the future of cannabinoids in the United States.

• LEARNING OBJECTIVES

• What are Cannabinoids
• Legal Status of Cannabinoids
• How was Epidolex approved
• Current marketing of CBD
• Research on Cannabinoids
• Possible future Cannabinoids
   
• WHY SHOULD YOU ATTEND

This training will provide valuable information to those who decide which products to pursue and those who develop them or submit their applications

• AREAS COVERED

• General  Information about Cannabinoids
• Grounds for the recent approval of Epidolex
• Clinical Trials for Epidolex
• Legal and Illegal marketing of CBD
• Research being conducted on CBD
• Possible future of cannabinoid drugs

• WHO WILL BENEFIT?

• Regulatory Affairs
• Research and Development
• New Product selection

• SPEAKER

Dr. Loren Gelber is currently an independent consultant, based in Charlotte, NC.She previously was employed by Akesis, Bestsweet, RRI, Andrx, Royce, Universal Research, Danbury Pharmacal, Barr and the US FDA. She has been in Regulatory Compliance, Regulatory Affairs, Clinical Research and Quality Control Laboratories.